NurExone Biologic Inc. Opens the Market
TORONTO, July 4, 2022 /CNW/ – Representatives from NurExone Biologic Inc. (“NurExone” or the “Company”) (TSXV: NRX) and their team joined Yossi Boker, TMX Head of Business Development, Israel to celebrate the Company’s listing on TSX Venture Exchange and open the market.
NurExone is a pharmaceutical company developing a biological extracellular vesicles (EV)-based technology drug platform. This is a unique advanced treatment for reversing paralysis and improving the quality of life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified siRNA sequence.
For Market Openings: Media may pick up a feed from the TOC (television operations centre) for all market open ceremonies. The feed is named TSX Transmit 1 (SD-SDI) and is produced at the TMX Broadcast Centre and sent live to the TOC. To pick up the feed via the Dejero network, please contact email@example.com
SOURCE TSX Venture Exchange
The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.